Amycretin: a multi-mechanism drug in a pill

TL;DR

• One molecule, two hormones - amycretin activates the GLP-1 and amylin receptors at once, where CagriSema uses two separate agents.
• ~22% weight loss at 36 weeks in early-phase data published in The Lancet - unusually fast for this class.
• Pill and injection both in development - an oral multi-mechanism option would be a first.
• In Phase 3 since 2025 - investigational, not approved, realistic availability around 2028.
• Class GI effects apply - dose-dependent nausea, vomiting and diarrhoea; lean-mass protection matters with rapid loss.
• There is no legitimate way to obtain amycretin now.

Educational content, not medical advice. No doses or protocols appear. Amycretin is investigational and not approved.

---

Amycretin is Novo Nordisk's bid to leapfrog its own combination drug. Where CagriSema combines two separate agents, amycretin is a single molecule that activates both the GLP-1 and amylin receptors at once - and, unlike most of the class, it's being developed as both a pill and an injection. Its early performance has turned heads: roughly 22% weight loss in just 36 weeks, fast enough to position it as a genuine rival to the strongest injectables and the triple agonist retatrutide. The honest frame: it's investigational, in Phase 3, and realistically around 2028 before it could reach patients. Here's why it matters.

What it is and how it works

Amycretin mimics two hormones in one molecule:

• GLP-1 - appetite suppression and glucose regulation
• Amylin - a complementary satiety pathway (the same lever cagrilintide adds in CagriSema; see the cagrilintide compound reference)

This dual-hormone approach resembles CagriSema but uses a single molecule rather than a combination therapy - which can simplify development and dosing. The standout feature is the oral version: an oral multi-mechanism approach would be a significant advance over anything currently available as a pill, where options are still limited and less potent than injections.

The data

Amycretin's early results were strong enough that Novo Nordisk advanced it to Phase 3 on the strength of early-phase data published in The Lancet. The headline: approximately 22% weight loss at 36 weeks - notable both for its magnitude and its speed (many trials run 68–80 weeks to reach comparable numbers). Both oral and injectable forms are in development. These are early data, and Phase 3 will be the real test, but they're enough to place amycretin among the most promising next-generation candidates.

Side effects and trade-offs

• Gastrointestinal - the expected nausea/vomiting/diarrhea of the class, dose-dependent.
• Early-stage uncertainty - the impressive numbers come from earlier trials; Phase 3 safety and durability data are still being generated.
• Muscle - as with all rapid loss, lean-mass protection applies.

Where it stands

Amycretin is investigational and not approved. It advanced to Phase 3 in 2025; realistic availability is around 2028, later than the filed options like CagriSema. It's a "watch this space" drug, not a near-term one - and there is no legitimate way to obtain it now.

The bottom line - and where to start

Amycretin is one of the pipeline's most exciting names: a single-molecule GLP-1 + amylin drug, in both pill and injection, with ~22% weight loss in early data at unusual speed. But it's Phase 3 and years out (~2028), and early numbers still have to survive pivotal trials. It's a strong reason to be optimistic about oral multi-mechanism therapy - not a reason to wait, when effective supervised options exist today.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore retatrutide.

Frequently asked questions

What is amycretin? An investigational Novo Nordisk drug - a single molecule that activates both the GLP-1 and amylin receptors - being developed as both a pill and an injection. It's in Phase 3, not approved.

How much weight does amycretin cause you to lose? Early data showed about 22% weight loss at 36 weeks, notable for both size and speed. These are early-phase figures from trials, not a dosing recommendation, and Phase 3 will confirm or revise them.

When will amycretin be available? It advanced to Phase 3 in 2025, with realistic availability around 2028, pending trial outcomes and review. It is not available now.

Related reading

• CagriSema · New weight-loss drugs 2026–2027 · Orforglipron · Semaglutide
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. Amycretin is investigational and not approved; early trial data and timelines change. Claims for the Malaysian market are subject to MAB requirements.

References

• Amycretin (Novo Nordisk): single-molecule GLP-1 + amylin receptor agonist; oral and injectable; advanced to Phase 3 (2025) on early-phase data published in The Lancet; ~22% weight loss at 36 weeks (early data). · GLP-1 class gastrointestinal profile and thyroid C-cell boxed warning.